AK
Aktis Oncology, Inc.
AKTS · NASDAQ
$24.06 -5.91% (-$1.51)
1M -2.87%
Market Cap $1.28B
P/E Ratio -
Div. Yield -
ROE 35.78%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 197.77x
P/E N/A
P/FFO N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 100.00%
FCF margin 1,134.54%
Net margin 980.93%
Quality
0 /100
Poor ROIC 31.79%
Asset turnover 0.02x
ROE 35.78%
Debt
100 /100
Low Current ratio 7.37x
Debt/Equity N/A
Debt/Assets N/A
Stability
47 /100
Moderate Beta 0.45x
Profitable years 0
EPS volatility 36.42%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AKTS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Roden
Employees
79
Headquarters
Boston
Upcoming events
12 NOV
Earnings
Upcoming earnings report